National Trial to Help Women with PCOS Led by Physician at OU Health

Physicians at the University of Oklahoma Health Sciences in Oklahoma City are leading a groundbreaking national clinical trial called REBALANCE. This trial aims to help women with polycystic ovary syndrome (PCOS) who are struggling with infertility. PCOS is a common hormonal disorder that causes irregular periods, excess androgen levels, and polycystic ovaries. PCOS affects about 10% of women of reproductive age and is a leading cause of infertility due to irregular or absent ovulation.

REBALANCE is testing a new device developed by May Health, designed to restore ovulation in women with PCOS. Karl Hansen, M.D., Ph.D., a reproductive endocrinologist at OU Health, and chair of the Department of Obstetrics and Gynecology at the OU College of Medicine, is leading the clinical trial and was the first in the United States to use this innovative device. For women who haven't had success with traditional treatments, this new device offers hope. It uses a minimally invasive procedure to stimulate ovulation, potentially increasing the chances of pregnancy. The trial will involve around 195 women across the U.S., and researchers will track how often ovulation occurs and other important outcomes like pregnancy rates and symptom improvements.

This trial represents a potential new treatment for PCOS-related infertility, but also underscores the commitment of OU Health and the University of Oklahoma College of Medicine tripartite mission to advancing patient care through clinical, innovative research, and educational mission.

Read more from the University of Oklahoma about the impact of the REBALANCE clinical trial.

Clinical Trial of Device Aims to Induce Ovulation in Women with Polycystic Ovary Syndrome